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Abstract
Background: Preparation of endometrial thickness in frozen-thawed embryo transfer
(FET) is extremely important, particularly in repeated implantation failure (RIF) patients.
Objective: This study aimed to investigate the clinical outcomes of FET cycles among
RIF women, based on the effects of administering gonadotropin-releasing hormone
(GnRH) agonist prior to estrogen-progesterone preparation of the endometrium.
Materials and Methods: In this randomized clinical trial, 67 infertile women who were
candidates for FET were divided into two groups: A) case group (n = 34), treated with
GnRH agonist prior to endometrial preparation and B) control group (n = 33), which
received the routine protocol. (6 mg daily estradiol started from second day) The clinical
outcomes) including chemical and clinical pregnancy, in addition to implantation rates,
were compared between the two groups.
Results: The results showed no significant differences in women’s age (p = 0.558),
duration (p = 0.540), type (p = 0.562), and cause of infertility (p = 0.699). Regarding
pregnancy and implantation rates, there was a trend toward an increase in the case
group; however, differences were not statistically significant.
Conclusion: Although our results showed no significant differences between groups.
Because there are trends to better results in case group larger sample size may show
significant difference.
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1. Introduction
Ovarian stimulation commonly increases the
number of available embryos for embryo transfer
(ET). Despite advances in assisted reproductive
technology (ART) over the past four decades,
some cycles still fail in terms of achieving live
birth following in vitro fertilization (IVF)/ET (1).
Embryo cryopreservation can be applied as
an important technique in ART programs to
avoid multiple ovarian stimulation protocols
in infertile couples. Embryo cryopreservation
programs enable the creation of surplus embryos
following IVF/intracytoplasmic sperm injection
(ICSI) to be stored and utilized at a later date
in a frozen-thawed ET (FET) cycle (2). Exact
synchronization between endometrial maturation
and embryo development is an essential factor for
successful implantation in FET cycles. Successful
FET was reported during a natural cycle following
spontaneous ovulation, stimulated cycles (3),
and hormone supplement cycles (4). Available
hormonal supplement protocols introduced for
endometrial preparation differ in terms of drug
type, administration route, dosage, and whether
or not gonadotropin-releasing hormone (GnRH)
analogs are used (5). Recently, in themost common
protocols, spontaneous ovulation prior to estradiol
and progesterone administration was avoided by
pituitary down-regulation with a GnRH agonist
(6).
One of the main challenges of ART programs
is repeated implantation failure (RIF). Several
treatment strategies have been suggested for
this problem (7). FET cycles can be timed with
ovulation in natural cycles or after endometrial
preparation following exogenous hormone
therapy (3, 6). Another protocol for controlled
endometrial preparation is using the GnRH
agonist prior to steroid administration, resulting
in ovarian function suppression, subsequently
creating synchronization between endometrial
and embryo development (8). Several studies
showed significant improvements in pregnancy
rates for both fresh (9, 10) and frozen cycles (11)
following GnRH agonist administration in infertile
women with endometriosis or adenomyosis.
Specifically, in FET cycles, it was reported
that pretreatment with a GnRH agonist in
patients with adenomyosis improved endometrial
receptivity, as well as pregnancy outcomes
(11).
The present study was conducted to
investigate the effects of GnRH agonist
administration on the implantation rate in
the FET cycles of women with RIF, prior to
estrogen-progesterone preparation of the
endometrium.
2. Materials and Methods
2.1. Participants
In the present randomized clinical trial, 67
infertile women with history of idiopathic RIF (at
least two implantation failures), undergoing FET
cycles in Yazd Reproductive Sciences Institute,
Yazd, Iran between August and November
2017 were randomly enrolled in two groups.
Randomization was done as computer generated.
The case group (n = 34) received 0.1 mg/day of
the GnRH agonist (Variopeptyl, VarianDarou, Iran),
subcutaneous, from day 21 of the cycle preceding
the actual FET cycle. On the second day of the
cycle, the dose of GnRH agonist was reduced to
0.05mg and 6mg/day oral estradiol valerate (2mg,
Aburaihan Co., Tehran, Iran) was also started.When
the endometrial thickness reached to 7.5 mm,
vaginal supplementation of Cyclogest® pessaries
(Cox Pharmaceuticals, Barnstaple, UK) at 400 mg
twice daily was started and the GnRH agonist was
also stopped.
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The control group (n = 33), received 6 mg/day
oral estradiol valerate (2 mg, Aburaihan Co.,
Tehran, Iran) from the second day of the cycle
without the GnRH agonist. In the two groups,
frozen-thawed embryos were transferred on the
fourth day of progesterone treatment. All women
with endometrial polyp, uterine myoma, and
uterine anomaly were excluded from the study
(Figure 1).
2.2. Embryo vitrification and thawing
Vitrification and warming procedures
were effected using RapidVitTM Cleave and
RapidWarmTM Cleave kits, respectively (Vitrolife
Inc., Gothenburg, Sweden), as per manufacturer
instructions. The quality of embryos was evaluated
24 h later, and those with less than 50%
fragmentation were selected for ET.
2.3. Clinical outcomes
Chemical pregnancy was defined by serum β
hCG > 50 IU/L, 14 days after ET. Clinical pregnancy
was approved by the detection of a fetal heartbeat
2 wk after positive β hCG. Implantation rate
was defined as the number of gestational sacs
per embryos transferred. Moreover, endometrial
thickness was observed in sagittal view via
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Figure 1. Study design flowchart.
2.4. Ethical consideration
The study protocol was approved by the
Ethics Committee of Yazd Reproductive Sciences
Institute, Shahid Sadoughi University of Medical
Sciences, Yazd, Iran (Code: IR.SSU.RSI.Rec.1396.1).
Written informed consent was provided by all
participants.
2.5. Statistical analysis
Statistical analysis was carried out using the
statistical package for the social sciences (SPSS
v. 14, Chicago, IL). Both Mann-Whitney U and chi-
square tests were performed where appropriate.
The level of significance was set at p-value <
0.05.
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3. Results
In the case group, three cycles were canceled
due to ovarian cyst (37 mm), endometrial failure
to reach a thickness of at least 7.5 mm, and
no embryo survival after thawing procedure. Two
cycles were also canceled in the control group
because no embryo survived following the thawing
procedure.
Finally, the number of cycles remaining was 31
in each group. No participants were lost to follow-
up in either group. No significant differences in
the demographic characteristics were observed
between the two groups (Table I). The two
groups were similar in endometrial thickness at
the start of progesterone therapy (8.70 ± 1.08
vs. 8.94 ± 1.33, p = 0.521) and in the number
and quality of transferred embryo per women
(1.90 ± 30 vs. 1.83 ± .52, p = 0.554) (Table
I).
As presented in Table II, the ART outcomes
in the two groups were not significantly
different. Data showed higher chemical and
clinical pregnancy rates for the case group
than the control group (29% vs. 22.6% and
25.8% vs. 19.4%, respectively); however,
differences were not significant. Moreover,
implantation rate showed no statistically significant
difference between groups; however, there
was a trend toward greater implantation rate
in the case group (13.55% vs. 10.52%, p =
0.521).
Table I. Comparison of demographic characteristics in two study groups
Variables Case group (n = 31) Control group (n = 31) p-value
Age (y)* 32.61 ± 4.40 31.96 ± 4.22 0.558𝑎
Duration of infertility (y*) 6.93 ± 3.94 7.48 ± 2.99 0.540𝑎
Type of infertility **
Primary 22 (71.0) 24 (77.4)
Secondary 9 (29.0) 7 (22.6)
0.562𝑏
Cause of infertility *
Male factor 9 (29.0) 13 (41.9)
Poly cystic ovarian
syndrome
5 (16.1) 4 (12.9)
Tubal factor 3 (9.7) 1 (3.2)
MIX 9 (29.0) 8 (25.8)
Unexplained 5 (16.1) 4 (12.9)
Ovarian factor 0 (0.0) 1 (3.2)
0.699𝑏
Endometrial thickness (mm)* 8.70 ± 1.08 8.94 ± 1.33 0.521𝑏
Cycle day* 15.38 ± 2.29 16.38 ± 1.92 0.068𝑏
No. of transferred embryos* 1.90 ± 30 1.83 ± 0.52 0.554𝑏
Embryo quality **
Grade A 22 (71) 20 (64.5)
Grade B 7 (22.6) 5 (16.1)
Grade C 2 (6.5) 6 (19.4)
0.297𝑏
* Data presented as Mean ± SD. ** Data presented as n (%)
a: Mann-Whitney U test, b: Chi-square
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Table II. ART outcomes for the case group vs. control group
Variables Case group (n = 31) Control group (n = 31) p-value
Chemical pregnancy 9 (29.0) 7 (22.6) 0.562
Clinical pregnancy 8 (25.8) 6 (19.4) 0.544
Implantation rate 8/52 (13.55) 6/57 (10.52) 0.521
Data presented as n (%). Analyzed by Chi-square test
4. Discussion
The present study found that pituitary down-
regulation prior to frozen ET did not lead
to significantly higher chemical and clinical
pregnancy rates in women with a history of
RIF.
RIF is an important challenge in ART
programs for both patients and physicians.
An important factor in implantation is
synchronization between embryo development
and endometrial maturation. One study have
evaluated other factors that may affect or
improve ART outcome of frozen-thawed embryos
(1).
The programmed cycle using a GnRH agonist
prior to estrogen and progesterone administration
aims to effect pituitary down-regulation, thereby
avoiding spontaneous ovulation and cycle
cancelation, the primary drawbacks of a natural
cycle protocol (12). Our study revealed that
the GnRH agonist in women with RIF may
improve implantation and pregnancy rates;
however, indicated differences showed no
level of significance. Hebisha and colleagues
showed that daily subcutaneous administration
of 0.1 mg GnRH agonist (Triptorelin) prior to
estrogen and progesterone (starting from the
mid-luteal phase of the previous cycle) increased
implantation and pregnancy rates (13). A recent
study related to sample size also delivered
meaningful results. The implementation of a
smaller case group in our study was the reason
we did not report significant statistical results.
Furthermore, using the GnRH agonist prior to
frozen ET in polycystic ovary syndrome, women
indicated an improvement in ongoing pregnancy
rate (14).
Similarly, Xing and associates found that
hormonally controlled endometrial preparation
with prior GnRH agonist suppression can
be used for patients who had experienced
repeated IVF treatment failures, despite having
morphologically optimal embryos. This study
administered two intramuscular injections of
Diphereline (2.5 mg), with a duration time of 28
days between the first and second injection.
The comparison showed that clinical outcomes
were significantly better with GnRH agonist
protocols when compared with endometrial
preparation with estrogen and progesterone only
protocols in the same patients (15). Generally,
the underlying mechanism of a GnRH agonist
is not yet clearly understood. Probably It
seems that induces pituitary suppression and
decreased circulating estrogen, a GnRH agonist
may reduce concentrations of peritoneal fluid
metalloproteinase tissue inhibitors, down-regulate
peritoneal fluid inflammatory proteins, and
promote apoptosis and expression of pro-
apoptotic proteins (16, 17). Niu and colleagues
showed using long-term GnRH agonist prior to
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IVF/ICSI in infertile women with endometriosis
or adenomyosis significantly enhanced the
chances of pregnancy in both fresh and
frozen cycles (11). In fact, it was found that
women with repeated implantation failure
have concomitant uterine adenomyosis and
a prominent aggregation of macrophages
within the superficial endometrial glands, that
interrupted with embryo implantation. Tremellen
and colleagues showed that pituitary suppression
with a GnRH agonist increased implantation rate
(18).
In agreement with our result, Dal and colleagues
reported no difference in implantation and
pregnancy rates with or without the use of a
GnRH agonist for pituitary suppression in FET
cycles. They administered 3.75 mg Decapeptyl
in the mid-luteal phase of the cycle. Their results
indicated that endometrial preparation with
GnRH agonist pretreatment did not increase the
success rate of FET cycles (19). Previously, we
found no significant different implantation or
pregnancy rates when using exogenous steroids
with or without GnRH agonist during FET cycles
(20).
5. Conclusion
In conclusion, our study found that the use of
a GnRH agonist in women with RIF may improve
endometrial receptivity and increase pregnancy
rate. However, differences were not statistically
significant. Therefore, additional large prospective
studies are necessary on this topic.
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